ORPHA:659707
Yersinia pseudotuberculosis infection
Also known as: Y. pseudotuberculosis infection
Publications
21,166
Trials
0
Interventional, condition-specific
Researchers
1,240
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007024
- MeSH:D015012
- UMLS:C0043410
Additional Mondo synonyms (2)
infections, Yersinia pseudotuberculosis · pseudotuberculosis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
21,166 matched papers (7,994 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
1 associated chemical. Therapeutic evidence is listed first when present — not a treatment recommendation.
- zosterin · therapeutic
Literature
Is anyone studying this?
21,166
21,166 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
21,166 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
7,994 in the last 10 years · low confidence
Phrase hits: 21,166 · MeSH hits: 18
Who's working on it?
1,240
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wang Y13 papers · 2026
State Key Laboratory for Crop Stress Resistance and High-Efficiency Production, Shaanxi Key Laboratory of Agricultural and Environmental Microbiology, College of Life Sciences, Northwest A&F University, Yangling, Shaanxi 712100, P.R. China.
Papers in Europe PMC - 02Sebbane F9 papers · 2026
Univ. of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL -Center for Infection and Immunity of Lille, Lille, France.
Papers in Europe PMC - 03Wang Z9 papers · 2026
State Key Laboratory for Crop Stress Resistance and High-Efficiency Production, Shaanxi Key Laboratory of Agricultural and Environmental Microbiology, College of Life Sciences, Northwest A&F University, Yangling, Shaanxi 712100, P.R. China.
Papers in Europe PMC - 04Borsuk S7 papers · 2026
Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brasil. sibeleborsuk@gmail.com.
Papers in Europe PMC - 05Abdel Z6 papers · 2026
M. Aikimbayev's National Scientific Center for Especially Dangerous Infections, 14 Zhakhanger St., Almaty A35P0K3, Kazakhstan.
Papers in Europe PMC - 06Abdeliyev B6 papers · 2026
M. Aikimbayev's National Scientific Center for Especially Dangerous Infections, 14 Zhakhanger St., Almaty A35P0K3, Kazakhstan.
Papers in Europe PMC - 07Abdirassilova A6 papers · 2026
M. Aikimbayev's National Scientific Center for Especially Dangerous Infections, 14 Zhakhanger St., Almaty A35P0K3, Kazakhstan.
Papers in Europe PMC - 08Zhumadilova Z6 papers · 2026
M. Aikimbayev's National Scientific Center for Especially Dangerous Infections, 14 Zhakhanger St., Almaty A35P0K3, Kazakhstan.
Papers in Europe PMC - 09Avican K5 papers · 2026
Department of Molecular Biology, Umeå University, Umeå, Sweden.
Papers in Europe PMC - 10Brodsky IE5 papers · 2025
Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 60 · after dedupe 60 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 60 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (60)
- ctis·2026-526289-25-00·Authorised·VATS or Intrapleural Enzymatic Therapy for patientS with empyema (the VIETS trial)
skipped — LLM skipped (--skip-llm)
- ctis·2026-525632-41-00·Authorised·Randomized Controlled Trial Assessing the Effectiveness and Safety of Fecal Microbiota Transfer for VRE Eradication in Immunocompromised Patients (EU CTR, Phase II) – VRE-ex
skipped — LLM skipped (--skip-llm)
- ctis·2025-524744-36-00·Authorised·DOXYCYCLINE PENETRATION INTO BONE AND JOINT.
skipped — LLM skipped (--skip-llm)
- ctis·2025-524842-89-00·Authorised·HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)
skipped — LLM skipped (--skip-llm)
- ctis·2026-525972-25-00·Authorised·FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria
skipped — LLM skipped (--skip-llm)
- ctis·2025-525020-99-00·Authorised·PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin
skipped — LLM skipped (--skip-llm)
- ctis·2024-519985-35-00·Authorised·Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial
(OBLUMEN)
skipped — LLM skipped (--skip-llm)
- ctis·2024-517888-23-00·Authorised·Model-informed precision dosing for linezolid: a randomized clinical trial
skipped — LLM skipped (--skip-llm)
- ctis·2026-526444-13-01·Authorised·Preventing urinary tract infections in infants and young children with probiotic E. coli Nissle: FinNissle randomized controlled trial
skipped — LLM skipped (--skip-llm)
- ctis·2026-526270-17-00·Authorised·Early switch to oral antibiotic therapy in vertebral osteomyelitis: a multicentre, open-label, randomised, active control, parallel group, non-inferiority trial (sWITCH-VO)
skipped — LLM skipped (--skip-llm)
- ctis·2024-514894-22-01·Authorised·Nasal application of Staphylococcus lugdunensis for decolonization of Staphylococcus aureus – a first-in-human proof-of-concept microbiome intervention study
skipped — LLM skipped (--skip-llm)
- ctis·2026-526168-19-00·Authorised·Phase I Safety and Immunogenicity Study of a Multivalent Gonorrhoea Vaccine
skipped — LLM skipped (--skip-llm)
- ctis·2026-525594-39-00·Authorised·Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults.
(FAST 7)
skipped — LLM skipped (--skip-llm)
- ctis·2025-521493-33-00·Authorised·Macroleave: Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial
skipped — LLM skipped (--skip-llm)
- ctis·2025-520783-17-01·Authorised·Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 — ALACARTE trial)
skipped — LLM skipped (--skip-llm)
- ctis·2026-525790-39-00·Authorised·A study to investigate the repeat-dose pharmacokinetics of a combined oral contraceptive when given alone and in combination with ganfeborole in female participants of non-childbearing potential.
skipped — LLM skipped (--skip-llm)
- ctis·2026-525221-21-01·Authorised·Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
skipped — LLM skipped (--skip-llm)
- ctis·2026-526149-91-00·Authorised·Efficacy and safety of Dalbavancin in the treatment of infective Endocarditis caused by gram-positive cocci
skipped — LLM skipped (--skip-llm)
- ctis·2025-525058-20-00·Authorised·CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
skipped — LLM skipped (--skip-llm)
- ctis·2025-524312-11-00·Authorised·Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial
skipped — LLM skipped (--skip-llm)
- ctis·2026-525871-24-00·Authorised·Supplementary Oxygen Therapy after Limb Debridement and Reconstruction Surgery in Infected Extremity Fractures (SOLDIER): a pilot, non-blinded, randomized controlled trial
skipped — LLM skipped (--skip-llm)
- ctis·2025-522114-23-00·Authorised·A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy
skipped — LLM skipped (--skip-llm)
- ctis·2025-524487-37-00·Authorised, recruiting·Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)
skipped — LLM skipped (--skip-llm)
- ctis·2025-524092-23-00·Authorised, recruiting·A Phase 3 prospective, randomized, multicenter, active-controlled study to evaluate the efficacy and safety of BV100 plus low-dose polymyxin B compared with colistin plus high-dose ampicillin/sulbactam in the treatment of adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex
skipped — LLM skipped (--skip-llm)
- ctis·2026-525355-93-00·Authorised·PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, NON-INFERIORITY CLINICAL-TRIAL TO ASSESS THE EFFICACY AND SAFETY OF SHORT OUTPATIENT AMOXICILLIN REGIMENS IN CHILDREN WITH ACUTE STREPTOCOCCAL PHARYNGOTONSILLITIS (STOP – TRIAL)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Yersinia pseudotuberculosis infection — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Yersinia pseudotuberculosis infection" OR "Y. pseudotuberculosis infection" OR "infections, Yersinia pseudotuberculosis" OR "pseudotuberculosis"
MeSH descriptor terms unioned into the query: Yersinia pseudotuberculosis Infections
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Yersinia pseudotuberculosis infection" OR "Y. pseudotuberculosis infection" OR "infections, Yersinia pseudotuberculosis" OR "pseudotuberculosis" OR "Yersinia pseudotuberculosis Infections"
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (21166) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T20:07:10.641Z